Edition:
United States

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

31.49USD
2:03pm EDT
Change (% chg)

$0.05 (+0.16%)
Prev Close
$31.44
Open
$31.44
Day's High
$31.72
Day's Low
$30.81
Volume
92,766
Avg. Vol
235,888
52-wk High
$49.63
52-wk Low
$27.63

IPXL.OQ

Chart for IPXL.OQ

About

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $2,320.72
Shares Outstanding(Mil.): 73.81
Dividend: --
Yield (%): --

Financials

  IPXL.OQ Industry Sector
P/E (TTM): 65.57 35.76 36.62
EPS (TTM): 0.48 -- --
ROI: 2.24 15.33 14.52
ROE: 3.56 16.37 15.68

UPDATE 2-Teva, Allergan win U.S. antitrust approval for generics deal

WASHINGTON, July 27 Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest 79 generic drugs to rival firms, the Federal Trade Commission said on Wednesday.

Jul 27 2016

Impax buys generic drugs from Teva, Allergan for $586 million

Impax Laboratories Inc said it would buy a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.

Jun 21 2016

UPDATE 2-Impax buys generic drugs from Teva, Allergan for $586 mln

June 21 Impax Laboratories Inc said it would buy a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.

Jun 21 2016

BRIEF-Impax signs agreements to acquire generic products from Teva, Allergan

* Expects 2016 total company revenues to increase at least 15% over full year 2015

Jun 21 2016

Impax buys portfolio of generic products from Teva, Allergan

June 21 Impax Laboratories Inc said it would buy a portfolio of generic products from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.

Jun 21 2016

Shkreli's former company beats Impax demand to block drug sales

NEW YORK Turing Pharmaceuticals does not have to recall thousands of bottles of a life-saving medicine that became the flashpoint of a pricing controversy after former Chief Executive Martin Shkreli raised its price by over 5,000 percent, a U.S. judge ruled on Wednesday.

May 18 2016

Shkreli's former company beats Impax demand to block drug sales

NEW YORK Turing Pharmaceuticals does not have to recall thousands of bottles of a life-saving medicine that became the flashpoint of a pricing controversy after former Chief Executive Martin Shkreli raised its price by over 5,000 percent, a U.S. judge ruled on Wednesday.

May 18 2016

Shkreli's former company beats Impax demand to block drug sales

NEW YORK, May 18 Turing Pharmaceuticals does not have to recall thousands of bottles of a life-saving medicine that became the flashpoint of a pricing controversy after former Chief Executive Martin Shkreli raised its price by over 5,000 percent, a U.S. judge ruled on Wednesday.

May 18 2016

BRIEF-Impax Q1 GAAP loss per share $0.15

* Restructuring plan currently expected to achieve annualized cost savings of between $23 million to $27 million, beginning in 2017

May 10 2016

BRIEF-U.S. FTC sues Endo Pharma,Others for blocking Generic Versions Of some branded drugs

* FTC Sues Endo Pharmaceuticals Inc. And Others For Illegally Blocking Lower-Cost Generic Versions Of The Branded Drugs Opana Er And Lidoderm

Mar 31 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.